English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, November 14, 2018
エーザイ、「IR優良企業大賞」を受賞
Eisai Receives "IR Grand Prix Award"
Monday, November 12, 2018
エーザイ、中国において「レンビマ」(レンバチニブ)を新発売
Eisai Launches Lenvima (Lenvatinib) in China
Friday, November 9, 2018
エーザイとMSD、「レンビマ」(レンバチニブ)と「キイトルーダ」(ペムブロリズマブ)との併用療法について3がん腫に対する最新の研究成果を第33回がん免疫学会年次総会にて発表
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Thursday, November 8, 2018
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence
エーザイとEAファーマ、抗フラクタルカイン抗体E6011のクローン病治療薬開発で産学官連携の契約を締結し、研究開発を開始
エーザイ、中国の新蘇州工場が本格稼働
Eisai Commences Full-Scale Operation of New Suzhou Plant in China

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: